CDA | Evidence Driven
CDA | Evidence Driven

Ibrance for Advanced Breast Cancer Resubmission – Details

Details

Files
Generic Name:
Palbociclib
Project Status:
Complete
Therapeutic Area:
Advanced breast cancer
Manufacturer:
Pfizer Canada Inc.
Brand Name:
Ibrance Resubmission
Project Line:
Reimbursement Review
Project Number:
PC0093-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
75mg, 100mg and 125mg Capsules
Tumour Type:
Breast
Indications:
Advanced Breast Cancer
Funding Request:
In combination with letrozole, for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease
Sponsor:
Pfizer Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Palbociclib (Ibrance) Resubmission ABC – pERC Final Recommendation Final Recommendation November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Final Clinical Guidance Report Guidance Reports November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Final Economic Guidance Report Guidance Reports November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – pERC Initial Recommendation Initial Recommendation November 3, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – PAG Feedback on Initial Recommendation Feedback November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Manufacturer Feedback on Initial Recommendation Feedback November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Patient Advocacy Group (ReThink) Feedback on Initial Recommendation Feedback November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Patient Advocacy Group (CBCN) Feedback on Initial Recommendation Feedback November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Patient Advocacy Group COI Declarations COI Declarations November 21, 2016 View PDF
Palbociclib (Ibrance) Resubmission ABC – Clinician COI Declarations COI Declarations November 21, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : December 6, 2016